The investigation of effect of Hab-o Shefa in control of withdrawal symptoms in opioid addicts.
Phase 3
- Conditions
- Opioid addiction.Mental and behavioural disorders due to use of opioids
- Registration Number
- IRCT201109107518N1
- Lead Sponsor
- Studies and Research afair of University shahed.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 90
Inclusion Criteria
Opioids addiction according to DSM IV; Age between 25 to 40 years old; male; Posittive urinary morphine test? Exclusion criteria: Addiction to stimulants or alchole; Acute incontrollable to physical disease; antisocial or borderline personality or inability to answer questionnaire; Not patient consent for the study; Severe withdrawal symptoms or complications and drug allergies; Beginning of the study positive urinary stimulants test or negative urinary morphine test
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according to DSM IV.;Objective withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according to DSM IV.;Subjective withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according DSM IV.;Depression Bek. Timepoint: Daily. Method of measurement: Bek questionaire.;Depression Hamilton. Timepoint: Daily. Method of measurement: Hamilton questionair.;Craving on opioids. Timepoint: Daily. Method of measurement: Halikas questionaire.
- Secondary Outcome Measures
Name Time Method Adverse effect of Hab-o-Shefa and Clonidine. Timepoint: Daily. Method of measurement: Accordingto Traditional Iranian Medicine refrences and textbook of Katzong: tachicardic arrythmia, Blurred vision, Changes in vision- photophobia, constipation, urinary disorder, vertigo, Sleep disorders, Dry mouth, nausea and vomitting, flashing.